Human Papillomavirus (Cervical Cancer)

Company to Offer Latest HPV Test

Published in Women's Health Weekly, February 5th, 2000

Digene Corporation and Laboratory Corporation of America Holdings (LabCorp) announced that they have entered into an agreement whereby LabCorp will use the Digene Hybrid Capture II HPV Test for women with ASCUS (atypical squamous cells of undetermined significance) or borderline Pap smear results.

Under the terms of the agreement, LabCorp will offer Digene's advanced DNA-based technology, which detects the human papillomavirus (HPV), the cause of virtually all cervical cancer.

Every year in the United States, approximately 15,000 women are diagnosed with cervical cancer and 5,000 women die of the disease. Worldwide, cervical cancer affects 500,000...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2000-02-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry